General Dermatology

A new qualitative study finds that patients with hard-to-heal wounds routinely engage in protective and monitoring behaviors at home without recognizing those efforts as meaningful contributions to their own care.

The 3-phase Isoclear regimen pairs topical isotretinoin with clindamycin, tranexamic acid, niacinamide, and copper peptide based on treatment stage.

Nearly 68% of AD patients and 78% of psoriasis patients on topical-only regimens expressed a desire for systemic therapy, reflecting widespread skepticism about topicals as a long-term strategy.

HCW9302 selectively expands Treg cells to suppress autoreactive follicular inflammation without broad immunosuppression.

In a pivotal trial, two-thirds of skinvive neck patients maintained clinically significant improvement at six months.

Cosibelimab joins cemiplimab and pembrolizumab as a first-line option for advanced cSCC unsuitable for curative surgery or radiation.

Does this structured nighttime skin care routine actually work or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

In clinical practice, digital twins could predict how individual patients respond to treatments based on factors such as genetics, skin barrier function, and lifestyle patterns.

The review emphasizes that psychological stress can influence inflammatory pathways involved in CSU, potentially worsening disease activity.

More than 35% of zasocitinib-treated patients reached complete skin clearance at week 16, with treatment curve separation emerging as early as week 8.

Findings support ongoing pharmacovigilance monitoring of GLP-1 receptor agonists for hair loss, particularly as semaglutide and tirzepatide use continues to expand.

The priority review pathway cuts the standard 300-day Canadian review timeline to approximately 180 days, reflecting Health Canada's assessment of serious unmet need in the EB population.

In clinical medicine and science, robust often fails because it lacks quantifiable meaning.

The June issue of Dermatology Times highlights the latest advances in skin cancer, psoriasis, atopic dermatitis, hidradenitis suppurativa, and emerging dermatology technologies.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Phase 1/2 data from RESET-Myositis, RESET-SSc, and RESET-SLE presented at EULAR 2026 show durable immunomodulator-free responses and a consistent safety profile across indications.

Experts recommend routine genital assessment as part of comprehensive skin exams rather than relying on patient-initiated reporting of this sensitive manifestation.

Discover how oral GliSODin delivers SOD to boost skin defense, enhance retinoids, and reduce UV damage and dark spots—backed by clinical trials.

Unlike approved AD biologics and JAK inhibitors targeting specific cytokine pathways, GX-03 is designed to modulate inflammatory signaling locally within the skin microenvironment.

Can misting hypochlorous acid every day improve skin, or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

This month’s podcasts highlight the latest clinical insights, emerging therapies, and evolving conversations shaping dermatology practice.

Learn more about the in-depth topics covered in the May 2026 print issue of Dermatology Times.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Dermatology Times is looking back on the top stories in dermatology from the month of May.

A review in JEADV Clinical Practice argues that deliberate nail examination in children can generate and narrow a differential diagnosis across virtually every organ system.